TARSUS PHARMACEUTICALS, INC. Inventory, Work in Process, Net of Reserves
TARSUS PHARMACEUTICALS, INC. (TARS) had Inventory, Work in Process, Net of Reserves of $1.36 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryWorkInProcessNetOfReserves · last filed 2026-08-06
- 2026-06-30: Inventory, Work in Process, Net of Reserves $1.36M.
- 2026-03-31: Inventory, Work in Process, Net of Reserves $1.63M.
- 2025-12-31: Inventory, Work in Process, Net of Reserves $1.41M.
- 2025-09-30: Inventory, Work in Process, Net of Reserves $1.00M.
| Period end | Inventory, Work in Process, Net of Reserves |
|---|---|
| 2026-06-30 | $1.36M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.63M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.41M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.00M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.58M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $764.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $614.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $1.59M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $1.20M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $677.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $392.00K 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |